title: The role of maintenance therapy in multiple myeloma.
abstract: Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased-approach, often consisting of initial induction therapy, consolidation and maintenance therapy. With an ever-growing landscape of treatment options, the approach to optimal therapy has become increasingly complex. Specifically, controversy surrounds the optimal use and duration of maintenance therapy. We conducted a comprehensive literature search to analyze the most current literature and to provide recommendations for maintenance therapy in multiple myeloma.
authors: Department of Hematology, University of Rochester, Rochester, NY, USA.
authors: B
authors: B
authors: Lipe
authors: Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
authors: R
authors: R
authors: Vukas
authors: Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.
authors: J
authors: J
authors: Mikhael
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014182:Transplantation, Autologous
chemical_list: D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide